In the past week, FULC stock has gone down by -10.78%, with a monthly decline of -63.05% and a quarterly plunge of -59.18%. The volatility ratio for the week is 5.53%, and the volatility levels for the last 30 days are 10.48% for Fulcrum Therapeutics Inc The simple moving average for the last 20 days is -6.66% for FULC’s stock, with a simple moving average of -57.87% for the last 200 days.
Is It Worth Investing in Fulcrum Therapeutics Inc (NASDAQ: FULC) Right Now?
The 36-month beta value for FULC is also noteworthy at 2.22. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 1 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for FULC is 52.73M, and at present, short sellers hold a 11.18% of that float. The average trading volume of FULC on October 11, 2024 was 1.67M shares.
FULC) stock’s latest price update
The stock price of Fulcrum Therapeutics Inc (NASDAQ: FULC) has dropped by -4.11 compared to previous close of 3.41. Despite this, the company has seen a fall of -10.78% in its stock price over the last five trading days. accesswire.com reported 2024-10-10 that NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics, Inc.”) (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that “its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.
Analysts’ Opinion of FULC
Many brokerage firms have already submitted their reports for FULC stocks, with H.C. Wainwright repeating the rating for FULC by listing it as a “Neutral.” The predicted price for FULC in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on September 13, 2024 of the current year 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to FULC, setting the target price at $4 in the report published on September 12th of the current year.
FULC Trading at -50.76% from the 50-Day Moving Average
After a stumble in the market that brought FULC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.13% of loss for the given period.
Volatility was left at 10.48%, however, over the last 30 days, the volatility rate increased by 5.53%, as shares sank -4.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -64.76% lower at present.
During the last 5 trading sessions, FULC fell by -10.78%, which changed the moving average for the period of 200-days by -47.93% in comparison to the 20-day moving average, which settled at $3.50. In addition, Fulcrum Therapeutics Inc saw -51.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FULC starting from Tourangeau Greg, who sale 236 shares at the price of $7.76 back on May 07 ’24. After this action, Tourangeau Greg now owns 11,571 shares of Fulcrum Therapeutics Inc, valued at $1,831 using the latest closing price.
Tourangeau Greg, the Vice President, Finance of Fulcrum Therapeutics Inc, sale 4,884 shares at $11.72 during a trade that took place back on Mar 08 ’24, which means that Tourangeau Greg is holding 11,807 shares at $57,219 based on the most recent closing price.
Stock Fundamentals for FULC
Current profitability levels for the company are sitting at:
- -0.4 for the present operating margin
- 0.98 for the gross margin
The net margin for Fulcrum Therapeutics Inc stands at -0.25. The total capital return value is set at -0.12. Equity return is now at value -7.37, with -6.81 for asset returns.
Based on Fulcrum Therapeutics Inc (FULC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -1.29. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -10.37.
Currently, EBITDA for the company is -108.49 million with net debt to EBITDA at 2.5. When we switch over and look at the enterprise to sales, we see a ratio of 1.56. The receivables turnover for the company is 23.1for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.07.
Conclusion
In summary, Fulcrum Therapeutics Inc (FULC) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
